Deciphera Pharmaceuticals, Inc.

NasdaqGS:DCPH Rapporto sulle azioni

Cap. di mercato: US$2.2b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Deciphera Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Deciphera Pharmaceuticals' Il CEO è Steve Hoerter, nominato in Mar2019, e ha un mandato di 5.25 anni. la retribuzione annua totale è $ 6.01M, composta da 12.3% di stipendio e 87.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.084% delle azioni della società, per un valore di $ 1.86M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.3 anni e 9 anni.

Informazioni chiave

Steve Hoerter

Amministratore delegato

US$6.0m

Compenso totale

Percentuale dello stipendio del CEO12.3%
Mandato del CEO5.3yrs
Proprietà del CEO0.08%
Durata media del management4.3yrs
Durata media del Consiglio di amministrazione9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Apr 30
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Diving Into Deciphera Pharmaceuticals

Apr 26

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Mar 13
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 02
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Sep 25
Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Jul 26
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Jun 22
Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

May 08
Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Apr 10
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Aug 29

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Jul 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Feb 11

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Nov 22

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Aug 26
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Deciphera Pharmaceuticals posts data from cancer studies at ASCO21

Jun 04

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

May 10
Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Steve Hoerter rispetto agli utili di Deciphera Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Mar 31 2024n/an/a

-US$190m

Dec 31 2023US$6mUS$738k

-US$195m

Sep 30 2023n/an/a

-US$194m

Jun 30 2023n/an/a

-US$187m

Mar 31 2023n/an/a

-US$182m

Dec 31 2022US$4mUS$703k

-US$179m

Sep 30 2022n/an/a

-US$221m

Jun 30 2022n/an/a

-US$258m

Mar 31 2022n/an/a

-US$286m

Dec 31 2021US$9mUS$676k

-US$300m

Sep 30 2021n/an/a

-US$274m

Jun 30 2021n/an/a

-US$258m

Mar 31 2021n/an/a

-US$255m

Dec 31 2020US$8mUS$650k

-US$266m

Sep 30 2020n/an/a

-US$271m

Jun 30 2020n/an/a

-US$263m

Mar 31 2020n/an/a

-US$218m

Dec 31 2019US$9mUS$435k

-US$192m

Sep 30 2019n/an/a

-US$157m

Jun 30 2019n/an/a

-US$126m

Mar 31 2019n/an/a

-US$126m

Dec 31 2018US$447kn/a

-US$100m

Compensazione vs Mercato: La retribuzione totale di Steve ($USD 6.01M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 5.62M ).

Compensazione vs guadagni: La retribuzione di Steve è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Steve Hoerter (53 yo)

5.3yrs

Mandato

US$6,010,712

Compensazione

Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Steven Hoerter
President5.3yrsUS$6.01m0.084%
$ 1.9m
Thomas Kelly
Executive VP9.3yrsUS$2.03m0.049%
$ 1.1m
Dashyant Dhanak
Executive VP & Chief Scientific Officerless than a yearUS$3.06m0%
$ 0
Daniel Martin
Senior VP & Chief Commercial Officer5.8yrsUS$1.58m0.036%
$ 801.7k
Matthew Sherman
Executive VP & Chief Medical Officer4.7yrsUS$2.13m0.084%
$ 1.8m
Kevin Brodbeck
Senior VP & Chief Technical Officerless than a yearNessun datoNessun dato
Jennifer Larson
Senior Vice President of Finance & Investor Relationsno dataNessun datoNessun dato
Jeffrey Held
Senior VP & General Counsel5.3yrsNessun datoNessun dato
Lisa Price
Senior VP & Chief Human Resources Officer2.4yrsNessun datoNessun dato
Jama Pitman
Senior VP & Chief Development Officer4.3yrsNessun dato0.040%
$ 876.3k
Margarida Duarte
Senior VP & Head of International3.3yrsNessun datoNessun dato
Rodrigo Soto
Senior Vice President of Clinical Development3.4yrsNessun datoNessun dato

4.3yrs

Durata media

53yo

Età media

Gestione esperta: Il team dirigenziale di DCPH è considerato esperto (durata media dell'incarico 4.3 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Steven Hoerter
President6.1yrsUS$6.01m0.084%
$ 1.9m
John Martin
Independent Director9.3yrsUS$388.59k0%
$ 0
Edward Benz
Independent Director7.7yrsUS$396.09k0%
$ 0
Patricia L. Allen
Independent Director7.8yrsUS$398.55k0%
$ 0
Ron Squarer
Independent Chairman4.5yrsUS$403.30k0%
$ 0
Jean-Yves Blay
Member of Scientific Advisory Board9yrsNessun datoNessun dato
James Bristol
Independent Director16.8yrsUS$414.77k0%
$ 0
John Condeelis
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Filip Janku
Member of Scientific Advisory Board9yrsNessun datoNessun dato
F. Hodi
Member of Scientific Advisory Board9yrsNessun datoNessun dato
Dennis Walsh
Independent Director9.3yrsUS$386.05k0.013%
$ 281.5k
John de Groot
Member of Scientific Advisory Boardno dataNessun datoNessun dato

9.0yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di DCPH sono considerati esperti (durata media dell'incarico 9 anni).